Targeting cell-cycle proteins has seen some headway in breast cancer treatment, such as using cyclin-dependent kinase (CDK4 and CDK6) inhibitors, but it is still considered in the early days of application [4]. This evidence concerns the gene CDK4 and breast carcinoma.